MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$2.05 +2.02%

+$0.08 today

Market cap
$131.01M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.57M

Average 0.98M

MGNX EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

MacroGenics, Inc.NASDAQ: MGNX

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$0.58, compared with -$0.65 a year earlier. Trailing-twelve-month EPS (Basic) was -$1.1.

Context

  • EPS (Basic) grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 2 analysts of -$1.61 (-36.8%) for the fiscal year ending Dec 2026, a slowdown from the -10.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.58-163.6% QoQ
Last fiscal yearDec 2025
-$1.18-10.3% YoY
LTMMar 2026
-$1.1-23.6% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.8%+86.3%+75.6 pp
1 year-10.3%-36.8%-26.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(1.18) USD
Year-over-year change
-10.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -23.6% is the 9th highest of 11, against a peer median of +9.8%.
MGNX Competitors
EPS (Basic) for MGNX and competitors
Company Period LTM YoY 3-year CAGR
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$2.65 USD+473.2%—
OVIDOvid Therapeutics Inc.LTM Mar 2026-$0.35 USD+1.2%—
CNTXContext Therapeutics Inc.LTM Mar 2026-$0.42 USD-15.1%—
IFRXInflaRx N.V.LTM Mar 2026-€0.61 EUR+18.5%—
STTKShattuck Labs, Inc.LTM Mar 2026-$0.63 USD+54.7%—
CNTBConnect Biopharma Holdings LimitedFY2025-$1 USD-257.1%—
MGNXMacroGenics, Inc.LTM Mar 2026-$1.1 USD-23.6%—
COYACoya Therapeutics, Inc.LTM Mar 2026-$1.15 USD-7.5%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$1.68 USD-1088.2%—
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$1.73 USD+44.9%—
CLNNClene Inc.LTM Mar 2026-$3.25 USD+24.7%—
Peer median (excluding MGNX) —+9.8%—

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$2.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.